313 related articles for article (PubMed ID: 20402558)
1. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
Perry CM
Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc first-line therapy for HIV infection. Too risky.
Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC; Rockstroh JK; Hardy WD
Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
[TBL] [Abstract][Full Text] [Related]
8. When and how to use maraviroc in HIV-infected patients.
Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
[No Abstract] [Full Text] [Related]
9. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
Vandekerckhove L; Verhofstede C; Vogelaers D
J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Meanwell NA; Kadow JF
Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
16. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
17. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
Yang H; Rotstein DM
Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
[TBL] [Abstract][Full Text] [Related]
18. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.
Poveda E; Paredes R; Moreno S; Alcamí J; Córdoba J; Delgado R; Gutiérrez F; Llibre JM; García Deltoro M; Hernández-Quero J; Pulido F; Iribarren JA; García F
AIDS Rev; 2012; 14(3):208-17. PubMed ID: 22833064
[TBL] [Abstract][Full Text] [Related]
19. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
[No Abstract] [Full Text] [Related]
20. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.
Poveda E; Alcamí J; Paredes R; Córdoba J; Gutiérrez F; Llibre JM; Delgado R; Pulido F; Iribarren JA; García Deltoro M; Hernández Quero J; Moreno S; García F
AIDS Rev; 2010; 12(3):135-48. PubMed ID: 20842202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
